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Background: We have previously shown that serum levels of glyceraldehyde-derived advanced glycation end
products (Gly-AGEs) are elevated under oxidative stress and/or diabetic conditions and associated with insulin
resistance, endothelial dysfunction and vascular inflammation in humans. Further, Gly-AGEs not only evoke oxidative
and inflammatory reactions in endothelial cells (ECs) through the interaction with a receptor for AGEs (RAGE), but
also mimic vasopermeability effects of AGE-rich serum purified from diabetic patients on hemodialysis. These
observations suggest that Gly-AGE-RAGE system might be a therapeutic target for vascular complications in diabetes.
However, since incubation of glyceraldehyde with proteins will generate a large number of structurally distinct AGEs, it
remains unclear what type of AGE structures could mediate the deleterious effects of Gly-AGEs on ECs.
Aims and Methods: Therefore, in this study, we examined (1) whether glyceraldehyde-derived pyridinium (GLAP),
one of the Gly-AGEs generated by the incubation of lysine with glyceraldehyde, elicited reactive oxygen species
(ROS) generation and inflammatory and thrombogenic gene expression in human umbilical vein ECs (HUVECs) via
the interaction with RAGE and (2) if DNA aptamers raised against Gly-AGEs or GLAP (AGE-aptamer or GLAP-aptamer)
inhibited the binding of GLAP to RAGE and subsequently suppressed the harmful effects of GLAP on HUVECs.
Results: GLAP stimulated ROS generation in a bell-shaped manner; GLAP at 10 μg/ml increased ROS generation in
HUVECs by 40%, which was blocked by the treatment with RAGE-antibody (RAGE-Ab). Ten μg/ml GLAP significantly
up-regulated mRNA levels of RAGE, monocyte chemoattractant protein-1, intercellular adhesion molecule-1, vascular
cell adhesion molecule-1 and plasminogen activator inhibitor-1 in HUVECs, which were also suppressed by RAGE-Ab.
AGE-aptamer or GLAP-aptamer significantly blocked these deleterious effects of GLAP on HUVECs. Moreover, quartz
crystal microbalance analyses revealed that GLAP actually bound to RAGE and that AGE-aptamer or GLAP-aptamer
inhibited the binding of GLAP to RAGE.
Conclusions: The present study suggests that GLAP might be a main glyceraldehyde-related AGE structure in Gly-AGEs
that bound to RAGE and subsequently elicited ROS generation and inflammatory and thrombogenic reactions in
HUVECs. Blockade of the GLAP-RAGE interaction by AGE-aptamer or GLAP-aptamer might be a novel therapeutic
strategy for preventing vascular injury in diabetes.
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Advanced glycation end products (AGEs) are formed by
the Maillard process, a non-enzymatic reaction between
reducing sugars and amino groups of proteins, lipids or
nucleic acids, that contributes to the aging of proteins
[1-3]. This process begins with the conversion of revers-
ible Schiff base adducts to more stable Amadori prod-
ucts [1-3]. Over the course of days to weeks, the
Amadori products undergo further rearrangement reac-
tions such as dehydration and condensation to form ir-
reversibly cross-linked macroprotein derivatives termed
AGEs [1-3]. The formation and accumulation of AGEs
in various tissues have been known to progress at a
physiological aging and at an accelerated rate under
hyperglycemic and/or oxidative stress conditions such as
diabetes [1-3]. There is accumulating evidence that
AGEs and the receptor for AGEs (RAGE) interactions
play a central role in the development and progression
of vascular complications [4-8]. Among various reducing
sugar-modified AGEs, we have previously shown that
serum levels of glyceraldehyde-derived advanced glyca-
tion end products (Gly-AGEs) are elevated under oxida-
tive stress, inflammatory and/or diabetic conditions and
associated with insulin resistance, endothelial dysfunc-
tion, vascular inflammation and decreased number and
migratory activity of endothelial progenitor cells in
humans [9-14]. Further, Gly-AGEs not only evoke oxida-
tive and inflammatory reactions in endothelial cells
(ECs) through the interaction with RAGE, but also
mimic vascular permeability effects of AGE-rich serum
purified from diabetic patients on hemodialysis [15-20].
These observations suggest that Gly-AGE-RAGE system
might be a therapeutic target for preventing vascular
complications in diabetes. However, since incubation of
glyceraldehyde with proteins will generate a large num-
ber of structurally distinct AGEs, it remains unclear
what type of AGE structures could mediate the deleteri-
ous effects of Gly-AGEs on ECs.
In 1990s, an in vitro-selection process called system-
atic evolution of ligands by exponential enrichment
(SELEX) was developed to screen aptamers, single-
stranded DNA or RNA molecules that can bind with
high affinity and specificity to a wide range of target pro-
teins [21]. Due to its small size, non-immunogenicity
and ease of modification compared to conventional
monoclonal antibodies, a couple of aptamers have been
used in the clinical fields as a tool for neutralizing func-
tion of various proteins [22,23]. Indeed, we have recently
found that high-affinity DNA aptamer directed against
Gly-AGEs (AGE-aptamer) inhibits the binding of Gly-
AGEs to RAGE and subsequently protects against the
Gly-AGE-induced inflammatory reactions in ECs and
mesangial cells, and suppresses the progression of ne-
phropathy in an animal model of type 2 diabetes,neointimal hyperplasia in balloon-injured rat carotid ar-
teries and melanoma growth in nude mice [24-27].
These findings indicate that AGE-aptamer could be a
valuable tool for blocking the deleterious effects of Gly-
AGEs in both cell culture and animal models. In this
study, to identify a main AGE structure in Gly-AGEs
that could mediate the biological actions, we examined
(1) whether glyceraldehyde-derived pyridinium (GLAP),
one of the Gly-AGEs generated by the incubation of
lysine with glyceraldehyde, elicited reactive oxygen spe-
cies (ROS) generation and inflammatory and thrombo-
genic gene expression in human umbilical vein ECs
(HUVECs) via the interaction with RAGE and (2) if
AGE-aptamer or DNA aptamer directed against GLAP
(GLAP-aptamer) inhibited the binding of GLAP to




D, L-Glyceraldehyde, bovine serum albumin (BSA) (essen-
tially fatty acid free and essentially globulin free, lyophi-
lized powder), and N-acetyl-L-lysine were purchased from
Sigma (St. Louis, MO, USA). Carboxy-H2DFFDA from
Life Technologies Japan (Tokyo, Japan).
Cells
HUVECs were cultured in endothelial basal medium
supplemented with 2% fetal bovine serum, human
fibroblast growth factor β, heparin, human epidermal
growth factor and hydrocortisone according to the
supplier’s instructions (Lonza Japan Ltd., Tokyo,
Japan). GLAP or carboxy-H2DFFDA treatment was
carried out in a medium lacking epidermal growth
factor and hydrocortisone.
Synthesis and purification of GLAP
GLAP was synthesized according to a slightly modified
method of Usui et al. [28]. In brief, glyceraldehyde
(0.2 M) and N-acetyl-L-lysine (0.1 M) were dissolved in
0.2 M sodium phosphate buffer (pH 7.4), and incubated at
37°C for a week. The reaction mixture was filtered with a
polyvinylidene difluoride membrane filter (0.22 mm,
Millipore, Bedford, MA, USA), and then put on a C8 col-
umn on preparative reversed phase high-performance li-
quid chromatography (HPLC). HPLC was done with a
quaternary gradient pump PU-2089 plus (JASCO Co. Ltd.,
Tokyo, Japan) and monitoring at 215 nm with the UV–
VIS spectrophotometric detector UV-2075 plus (JASCO
Co., Ltd. Tokyo, Japan) under the following conditions:
Column: COSMOSIL 5C8-AR-300 column (250 × 20 mm
I.D., Nacalai Tesque Inc., Kyoto, Japan). Elution: isocratic
of 25 mM sodium phosphate buffer (pH 7.0) from 0
to 30 min and a linear gradient of 0-40% acetonitrile
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30 to 60 min. Flow rate: 2 ml/min. Temperature: ambient.
Preparation of antibody directed against human RAGE
(RAGE-Ab)
RAGE-Ab, which recognizes the amino acid residues
167–180 of human RAGE protein, was used for neutral-
izing assays and prepared as described previously [29].
Immobilizing GLAP on agarose beads
GLAP was covalently coupled via carboxy groups to
amine groups on CarboxyLink Coupling Gel (Pierce,
Rockford, IL, USA) with crosslinker 1-Ethyl-3-(3-
dimethylaminopropyl) carbodiimide according to the
manufacturer's instructions.
SELEX
Preparation and selection of GLAP-aptamer were per-
formed as described previously [30]. Synthetic DNA
templates (106-mer) with 56 random nucleotides, 5’-
AGCTCAGAATGGATCCAAACGCTCA-(N)56-TTCG
ACATGAGAATTCGGCCGGATC-3’, were amplified
over 12 cycles of polymerase chain reaction (PCR)
(94°C, 20 seconds, 52°C, 20 seconds, and 72°C, 20 seconds)
using 5’- and 3’-primers. From the purified PCR products,
single-stranded DNAs were obtained by an additional
45 cycles of PCR using 5’-primer only. The single-
stranded DNA pool was then loaded onto a GLAP-
immobilized agarose column (3 mm × 10 mm). After
30 min, bound DNA was eluted with 0.3 mL of
phosphate-buffered saline (PBS) at 95°C. To remove
single-stranded DNAs that had non-specifically bound
to agarose beads, the eluted DNA was passed through a
control agarose column without GLAP immobilization.
The recovered single-stranded DNA was amplified by
PCR and used as the input DNA for the next selection.
After repeating the SELEX procedure seven times, se-
quences of cloned single-stranded DNAs were deter-
mined using an automatic sequencer (ABI PRISM;
Perkin-Elmer Applied Biosystems, Foster, CA, USA).
DNA aptamers are susceptible to degradation by nucle-
ases [25]. This will limit their applications for real sam-
ples, such as blood and tissues. To solve this issue, we
modified aptamers with phosphorothioate linkage at
each three bases.
Preparation of Gly-AGEs
Gly-AGEs were prepared as described previously [15].
In brief, BSA was incubated under sterile conditions
with glyceraldehyde for 7 days. Then, unbounded
sugars were removed by dialysis against PBS. Prepara-
tions were tested for endotoxin using Endospecy ES-
20S system (Seikagaku Co., Tokyo, Japan); no endotoxin
was detectable.Preparation and selection of AGE-aptamer
Preparation and selection of AGE-aptamer were per-
formed as described previously [24]. Sequences of AGE-




CGGGAG-3’. AGE- and Control-aptamer were modified
with phosphorothioate as described previously [24].Measurement of intracellular ROS generation
Intracellular formation of ROS was detected using a
fluorescent probe carboxy-H2DFFDA (Life Technologies
Japan., Tokyo, Japan) as described previously [31]. In
brief, HUVECs were incubated with 0.1% dimethyl sulf-
oxide (DMSO) in the presence or absence of 10 μM
carboxy-H2DFFDA for 1 hr. Then the cells were washed
with PBS three times, and treated with or without the
indicated concentrations of GLAP in the presence or
absence of 5 μg/ml RAGE-Ab, 100 nM AGE-aptamer,
Control-aptamer or GLAP-aptamer. After 10 min,
intracellular superoxide generation was measured with
an ARVO X3 fluorescent plate reader (PerkinElmer
Japan, Yokohama, Japan). ROS production was cal-
culated by subtracting the fluorescence for cells
pre-incubated with DMSO only from that with carboxy-
H2DFFDA.Real-time reverse transcription-PCR (RT-PCR)
HUVECs were treated with or without the indicated
concentrations of GLAP in the presence or absence of
5 μg/ml RAGE-Ab, 100 nM AGE-aptamer, Control-
aptamer or GLAP-aptamer for 4 hr. Then total RNA was
extracted with NucleoSpin RNA kit (Takara Bio Inc.,
Shiga, Japan) according to the manufacturer’s instructions.
Quantitative real-time RT-PCR was performed using
Assay-on-Demand and TaqMan 5 fluorogenic nuclease
chemistry (Life Technologies Japan Ltd., Tokyo, Japan)
according to the supplier’s recommendation. IDs of
primers for human RAGE, monocyte chemoattractant
protein-1 (MCP-1), intercellular adhesion molecule-1
(ICAM-1), vascular cell adhesion molecule-1 (VCAM-1),
plasminogen activator inhibitor-1 (PAI-1), and 18S gene
were Hs00542592_g1, Hs00234140_m1, Hs99999152_m1,
Hs01003372_m1, Hs01126604_m1, and Hs03003631_g1,
respectively.Secondary structure analyses of GLAP- and AGE-aptamers
Secondary structure analyses of GLAP- and AGE-aptamers
were performed using the computer program mFold sup-
ported by Zuker [32].
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GLAP-aptamer
The binding affinities of GLAP to extracellular AGE-
binding v-domain of RAGE (vRAGE), AGE-aptamer,
GLAP-aptamer or Control-aptamer were measured using
sensitive 27-MHz quartz crystal microbalance (QCM)
(Affinix Q; Initium Inc., Tokyo, Japan) under the presence
or absence of 2% fetal bovine serum (Lonza Group Ltd.,
Basel, Switzerland) as described previously [24,25]. In brief,
recombinant vRAGE, AGE-aptamer or GLAP was immobi-
lized on a QCM surface. After adding GLAP or GLAP-
aptamer to reaction vessel, the time course of the frequency
decrease of bound vRAGE, bound AGE-aptamer or bound
GLAP on the QCM was monitored. The binding affinities
of GLAP to vRAGE, AGE-aptamer or GLAP-aptamer were
calculated from curve fitting to the QCM frequency de-
crease as described previously [24,25].Statistical analysis
All values were presented as mean ± standard error.
Student’s t-test was performed for statistical compari-
sons; p < 0.05 was considered significant.Results
We first examined the effects of GLAP on ROS generation
in HUVECs. As shown in Figure 1A, GLAP increased
superoxide generation in HUVECs in a bell-shaped man-
ner; ROS generation began to be induced by 1 μg/ml
GLAP and reached a maximum by 10 μg/ml GLAP, and
the peak value was about 1.4-fold higher than the basal
level. RAGE-Ab completely blocked the increase in ROS
generation evoked by 10 μg/ml GLAP. Since ROS gener-
ation was maximumly induced by 10 μg/ml GLAP, we
chose the concentration of GLAP at 10 μg/ml for the
following experiments.
We next investigated the effects of GLAP on RAGE
gene expression in HUVECs. As shown in Figure 1B,
GLAP up-regulated RAGE mRNA levels in HUVECs,
which was also completely blocked by the treatment
with RAGE-Ab.
Secondary structure of GLAP-aptamer with phospho-
rothioate linkage was provided in Figure 1C. Phoshor-
othioate linkages are shown as bold line. These aptamers
showed typical stem-loop or bulge-loop structure with
cytosine-rich sequences such as ACC(C) or (C)CCA.
QCM is a technique to detect a mass change on an
electrode at nanogram level from the resonance fre-
quency change; when molecules bound on oscillating
quartz crystal, oscillating frequency decreases in propor-
tional to binding amount of molecules on the surface
[33]. As shown in Figure 1D, GLAP bound to vRAGE in
a dose-dependent manner; dissociation constant (KD)
value was 5.9 × 10−5 M.We further examined whether GLAP elicited inflam-
matory and thrombogenic gene expression in HUVECs.
As shown in Figure 2A-D, GLAP significantly up-
regulated MCP-1, ICAM-1, VCAM-1 and PAI-1 mRNA
levels in HUVECs, which was suppressed by the treat-
ment with RAGE-Ab.
DNA aptamers specific for GLAP were isolated by an
in vitro-selection process, SELEX, from a pool of ~1015
different nucleic acid sequences. In this study, 34 clones
were sequenced from the pool of selected single-stranded
DNAs. The length of sequence randomized in the original
library was 56 nucleotides; however, the length of the
inserts of the clones obtained ranged from 55 to 57 nucle-
otides, probably due to insertion or deletion during
PCR amplification. Sequence of GLAP-aptamer used for
the present experiments was GCGGGTTGGGAGCCAC
TAGTAGCAACGTGCGACCCTCTACGAAGCAAACC
ATCCTCA. Secondary structure of AGE-aptamer with
phosphorothioate linkage was provided in Figure 3A.
Phoshorothioate linkages are shown as bold line.
As shown in Figure 3B-E, AGE-aptamer or GLAP-
aptamer, but not Control-aptamer, bound to GLAP with
KD values of 3.3 × 10
−5 M and 0.26 × 10−5 M, respect-
ively, and inhibited the binding of GLAP to vRAGE. The
bindings of these aptamers to GLAP were not affected
under 2% fetal bovine serum conditions that mimic the
state in functional experiments of aptamers. Moreover,
GLAP-induced increase in ROS generation as well as
RAGE, MCP-1, ICAM-1, VCAM-1 and PAI-1 mRNA
levels of HUVECs were significantly inhibited by the





is a major compound found in Gly-AGEs, and its plasma
levels as well as the contents in tail collagen or brain of
diabetic rats are extremely increased compared with
normal rats [28,34,35]. However, its pathophysiological
role in vascular damage in diabetes is largely known. In
other words, it remains unclear whether GLAP could
mainly mediate the deleterious effects of Gly-AGEs on
HUVECs. Therefore, we first examined whether GLAP
mimicked the effects of Gly-AGEs in HUVECs. In this
study, we found that (1) GLAP increased ROS gener-
ation in HUVECs in a bell-shaped manner, (2) GLAP
up-regulated RAGE mRNA levels in HUVECs, (3) GLAP
actually bound to vRAGE, and (4) RAGE-Ab completely
prevented the GLAP-induced ROS generation and
RAGE gene induction in HUVECs. These findings
suggest the pathological crosstalk between ROS gener-
ation and RAGE gene induction in GLAP-exposed
HUVECs. So, engagement of RAGE with GLAP could
Figure 1 Effects of GLAP on ROS generation (A) and RAGE gene expression in HUVECs (B), secondary structure of GLAP-aptamer (C),
and binding affinity of GLAP to immobilized vRAGE (D). (A) HUVECs were incubated with 0.1% DMSO in the presence or absence of 10 μM
carboxy-H2DFFDA for 1 hr, and then treated with or without the indicated concentrations of GLAP in the presence or absence of 5 μg/ml RAGE-Ab.
After 10 min, intracellular superoxide generation was measured. * and **, p < 0.05 and p < 0.01 compared to the value without treatment, respectively. #,
p < 0.05 compared to the value with 10 μg/ml GLAP. N = 4 per group. (B) HUVECs were treated with or without 10 μg/ml GLAP in the presence or
absence of 5 μg/ml RAGE-Ab for 4 hr. Then total RNAs were extracted, transcribed and amplified by real-time PCR. Data were normalized
by the intensity of 18S mRNA-derived signals and then related to the value without treatment. #, p < 0.05 compared to the value with
10 μg/ml GLAP. N = 3-6 per group. (C) Secondary structure of GLAP-aptamer. Phoshorothioate linkages are shown as bold line. (D) GLAP at
1, 2 and 3 μg/ml was added on vRAGE-immobilized reaction vessel. The time course of the frequency decrease of bound vRAGE on the
QCM was monitored. Two-independent experiments were performed.
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RAGE expression, further potentiating the harmful ef-
fects of GLAP-RAGE axis in HUVECs. We have previ-
ously reported that Gly-AGEs up-regulate RAGE
mRNA levels in ECs via RAGE-mediated ROS gener-
ation [15,18-20,24]. Guglielmotto et al. recently found
that GLAP induced RAGE gene expression, and acti-
vated a redox-sensitive transcriptional factor, nuclear
factor-κB (NF-κB) pathway in neuroblastoma cells,
which was prevented by silencing RAGE using RNA
interference [35]. Given that RAGE is a major receptorfor AGEs that mediates the downstream signaling in
ECs and that ROS generation works as a second
messenger of RAGE [15,18-20,24], our present study
suggests that GLAP could mimic the deleterious ef-
fects of Gly-AGEs on HUVECs via the interaction with
RAGE, and the positive feedback loop between GLAP-
induced ROS generation and RAGE overexpression
might make a vicious cycle, promoting vascular dam-
age in diabetes.
In the present study, we also found for the first time
that GLAP significantly increased mRNA levels of MCP-
Figure 2 Effects of GLAP on MCP-1 (A), ICAM-1 (B), VCAM-1 (C), and PAI-1 gene expression in HUVECs (D). HUVECs were treated with or
without 10 μg/ml GLAP in the presence or absence of 5 μg/ml RAGE-Ab for 4 hr. Then total RNAs were extracted, transcribed and amplified by
real-time PCR. Data were normalized by the intensity of 18S mRNA-derived signals and then related to the value obtained with control. # and ##,
p < 0.05 and p < 0.01 compared to the value with 10 μg/ml GLAP alone, respectively. N = 3-6 per group.
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completely prevented by the treatment with RAGE-Ab.
Gly-AGEs are reported to up-regulate MCP-1, ICAM-1,
VCAM-1 and PAI-1 gene expression in ECs via ROS gen-
eration and transcriptional activation of NF-κB through
the interaction with RAGE [16-19,36-38]. Therefore,
the GLAP-RAGE axis could evoke inflammatory and
thrombogenic reactions in HUVECs by inducing ROS
generation. MCP-1 plays an important role in the early
phase of atherosclerosis by initiating monocyte recruit-
ment to the vessel wall, and its expression is elevated in
human atherosclerotic plaques [39,40]. The selective tar-
geting of CCR2, the receptor for MCP-1, markedly de-
creases atheromatous lesion formation in apoE knockout
mice [39,40]. One early phase of atherosclerosis involves
the firm adhesion of inflammatory cells to ECs as well,
whose process is mainly mediated by ICAM-1 and
VCAM-1 [41-43]. Moreover, attenuated fibrinolytic
activity due to increased PAI-1 levels is highlyprevalent in diabetic patients, thus contributing to the
increased risk of atherothrombosis and cardiovascular
disease in these subjects [44,45]. We have previously
shown that Gly-AGEs, RAGE and oxidative stress
marker, 8-hydroxydeoxyguanosine levels are increased
in thoracic aorta of obese and type 2 diabetic rats
compared with non-diabetic control rats, all of which
are associated with enhanced gene expression of
MCP-1, VCAM-1 and PAI-1 and NF-κB activation
[46]. Serum levels of Gly-AGEs are an independent
determinant of PAI-1 in a general population [47].
Taken together, these observations suggest that activation
of the GLAP-RAGE axis could play a role in the progres-
sion of atherosclerosis partly via induction of inflamma-
tory and thrombogenic reactions in ECs. The fact that
GLAP levels in plasma or tissue are extremely increased
in diabetic animals or patients [34,35] further supports the
pathological relevance of the GLAP-RAGE axis in acceler-
ated atherosclerosis in diabetes.
Figure 3 (See legend on next page.)
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Figure 3 Secondary structure of AGE-aptamer (A), binding affinities of GLAP to AGE-aptamer, GLAP-aptamer, or vRAGE (B-E) and
effects of AGE- or GLAP-aptamer on inflammatory and thrombogenic gene expression in GLAP-exposed HUVECs (F-K). (A) Secondary
structure of AGE-aptamer. Phoshorothioate linkages are shown as bold line. AGE-aptamer (B), GLAP ((C) and (D)) or recombinant vRAGE (E) was
immobilized on a QCM surface. After adding GLAP ((B) and (E)), GLAP-aptamer (C) or each aptamer (D) to reaction vessel, the time course of the
frequency decrease of bound AGE-aptamer (B), bound GLAP ((C) and (D)), or bound vRAGE (E on the QCM was monitored. Under no serum
conditions, solid line and circule. Under 2% fetal bovine serum conditions, dashed line and triangle. N = 3 per group. (F)-(K) HUVECs were treated
with or without 10 μg/ml GLAP in the presence or absence of 100 nM each aptamer for 4 hr. Then total RNAs were extracted, transcribed and
amplified by real-time PCR. Data were normalized by the intensity of 18S mRNA-derived signals and then related to the value obtained with
control. # and ##, p < 0.05 and p < 0.01 compared to the value with 10 μg/ml GLAP alone, respectively. N = 4 per group.
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As mentioned above, Gly-AGEs evoked oxidative, in-
flammatory and thrombogenic reactions in ECs via the
interaction with RAGE [15-20]. Furthermore, we have
found that Gly-AGEs exist in human serum, and the
levels are correlated with endothelial dysfunction and
vascular inflammation, surrogate markers for atheroscler-
otic cardiovascular disease [12,13]. In addition, Gly-AGEs
are immunologically distinct from other sugar-derived
AGEs or structurally identified AGEs such as glucose-,
glycolaldehyde-, fructose-, methylglyoxal-, glyoxal-modified
AGEs, carboxymethyllysine-BSA, carboxyethyllysine-BSA,
pyrraline-BSA, pentosidine-BSA, argpyrimidine-BSA, and
3-deoxyglucosone imidazolone-BSA [12,48]. These obser-
vations suggest that glyceraldehyde-related specific AGE
structure in Gly-AGEs might play a role in vascular in-
jury both in vitro and in vivo. Since GLAP mimicked
the deleterious effects of Gly-AGEs on HUVECs, it is
conceivable that GLAP is a cytotoxic AGE structure in
Gly-AGEs. However, it remains unclear whether AGE-
aptamer, which bound to Gly-AGEs, blocked the bind-
ing of Gly-AGEs to RAGE and resultantly inhibited the
Gly-AGE-evoked oxidative and inflammatory reactions
in cell culture and animal models [24-27,30,49], could
also inhibit the harmful effects of GLAP on HUVECs.
To address the issue, we investigated the effects of
AGE-aptamer on GLAP-evoked oxidative stress gener-
ation, RAGE, MCP-1, ICAM-1, VCAM-1 and PAI-1
gene induction in HUVECs. In this study, we found
that AGE- or GLAP-aptamer, but not Control-aptamer,
bound to GLAP and subsequently prevented the inter-
action of GLAP with RAGE. Moreover, GLAP-evoked
increase in ROS generation and up-regulation in
RAGE, MCP-1, ICAM-1, VCAM-1 and PAI-1 mRNA
levels were significantly blocked by the treatment with
AGE- or GLAP-aptamer, but not Control-aptamer. The
present findings suggest that GLAP is a target compound
for AGE-aptamer and might be a main glyceraldehyde-
related AGE structure in Gly-AGEs that interacted with
RAGE and subsequently elicited oxidative, inflamma-
tory and thrombogenic reactions in HUVECs. GLAP
was only formed in glyceraldehyde-modified BSA, not
in other sugar-modified one [34], further supporting
our speculation.Plasma or tissue concentration levels of GLAP in dia-
betic animals or patients are about 3–4 μg/ml [34,35].
So, the concentration of GLAP (1–10 μg/ml) used here
are comparable with those of the in vivo-diabetic situ-
ation. We did not know how GLAP formation was ac-
celerated under diabetic conditions. However, we, along
with others, have previously shown that hyperglycemia-
induced overproduction of superoxide by the mito-
chondrial electron transport chain activates the three
major pathways, including increased AGE formation,
and causes EC damage by inhibiting glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) activity [50,51].
Therefore, although glyceraldehyde, which could be de-
rived from glucose metabolism, is not a major sugar
in vivo, glyceraldehyde and glyceraldehyde-3 phosphate
could be increased under hyperglycemic and oxidative
stress conditions via reduced activity of GAPDH, which
might lead to promote the formation and accumulation
of GLAP in diabetes.
Limitations
Our study has a couple of limitations that should be
noted. First, we did not know whether AGE- or GLAP-
aptamer could bind to glucose-derived AGEs and inhibit
their biological effects on HUVECs. So, it would inter-
esting to compare the specificity of AGE- or GLAP-
aptamer against Gly-AGEs and glucose-derived AGEs,
which might confirm the value and specificity of the
aptamers. Seconds, we did not examine here the effect
of GLAP on atherosclerosis in diabetic animals. Third,
although GLAP levels in plasma and tail collagen or
brain were reported to increase in diabetic animal
[33,34], it remains unknown whether circulating GLAP
levels could be a biomarker of vascular injury in diabetic
patients. Lastly, AGEs induces cardiomyocyte autophagy
by, at least in part, inhibiting the phosphatidylinositol
3-phosphate kinase (PI3K)/Akt/mammalian target of
rapamycin (mTOR) pathway via RAGE [52], and AGEs-
induced macrophage migration is dependent on hepara-
nase involving RAGE-heparanase-PI3K/AKT pathway
[53]. In addition, RAGE activation leads to an increase
of transforming growth factor-beta1 levels [54]. There-
fore, complex and variable RAGE pathways might be in-
volved in the harmful actions of Gly-AGEs on HUVECs.
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these signaling pathways in HUVECs. Additional experi-
ments and further clinical studies are needed to clarify
the clinical relevance of GLAP-RAGE axis in accelerated
atherosclerosis in diabetes.
Conclusions
Our present observations suggest GLAP might be a
main glyceraldehyde-related AGE structure in Gly-AGEs
that bound to RAGE and subsequently evoked ROS gen-
eration and inflammatory and thrombogenic reactions in
HUVECs. Blockade of the GLAP-RAGE interaction by
AGE-aptamer or GLAP-aptamer might be a novel thera-
peutic strategy for preventing vascular injury in diabetes.
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